Tsutomu Iwasa

4.1k total citations
82 papers, 1.5k citations indexed

About

Tsutomu Iwasa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Tsutomu Iwasa has authored 82 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Tsutomu Iwasa's work include HER2/EGFR in Cancer Research (22 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Treatments and Mutations (14 papers). Tsutomu Iwasa is often cited by papers focused on HER2/EGFR in Cancer Research (22 papers), Cancer Treatment and Pharmacology (17 papers) and Lung Cancer Treatments and Mutations (14 papers). Tsutomu Iwasa collaborates with scholars based in Japan, United States and Australia. Tsutomu Iwasa's co-authors include Kazuhiko Nakagawa, Isamu Okamoto, Yuki Yamada, Erina Hatashita, Masahiro Fukuoka, Takeshi Yoshida, Junji Tsurutani, Eikichi Ihara, Minoru Suzuki and Kazuto Nishio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Tsutomu Iwasa

80 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tsutomu Iwasa Japan	23	765	539	455	187	182	82	1.5k
Sandra Krüger Germany	20	1.0k 1.3×	590 1.1×	645 1.4×	275 1.5×	277 1.5×	63	1.8k
Yong Tang China	17	791 1.0×	503 0.9×	629 1.4×	307 1.6×	280 1.5×	65	1.7k
Weixun Zhou China	20	596 0.8×	447 0.8×	571 1.3×	337 1.8×	269 1.5×	143	1.8k
Michael Vieth Germany	16	781 1.0×	570 1.1×	348 0.8×	124 0.7×	150 0.8×	35	1.7k
Tingguo Zhang China	26	451 0.6×	361 0.7×	626 1.4×	276 1.5×	178 1.0×	67	1.5k
Kunkun Sun China	16	402 0.5×	491 0.9×	409 0.9×	347 1.9×	210 1.2×	71	1.2k
Hisashi Shinohara Japan	24	590 0.8×	737 1.4×	492 1.1×	161 0.9×	301 1.7×	85	1.9k
Kyungeun Kim South Korea	22	352 0.5×	316 0.6×	510 1.1×	217 1.2×	71 0.4×	87	1.2k
Zhi Zhu China	23	479 0.6×	489 0.9×	634 1.4×	304 1.6×	203 1.1×	88	1.5k
Hiroyuki Komori Japan	19	500 0.7×	261 0.5×	483 1.1×	144 0.8×	374 2.1×	62	1.5k

Countries citing papers authored by Tsutomu Iwasa

Since Specialization

Citations

This map shows the geographic impact of Tsutomu Iwasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tsutomu Iwasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tsutomu Iwasa more than expected).

Fields of papers citing papers by Tsutomu Iwasa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tsutomu Iwasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tsutomu Iwasa. The network helps show where Tsutomu Iwasa may publish in the future.

Co-authorship network of co-authors of Tsutomu Iwasa

This figure shows the co-authorship network connecting the top 25 collaborators of Tsutomu Iwasa. A scholar is included among the top collaborators of Tsutomu Iwasa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tsutomu Iwasa. Tsutomu Iwasa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shiraishi, N., Takayuki Takahama, Kazuko Sakai, et al.. (2025). Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing. Thoracic Cancer. 16(3). e70007–e70007. 1 indexed citations

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2025). Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. Journal of Clinical Oncology. 43(11). 1302–1313. 5 indexed citations

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2024). Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).. Journal of Clinical Oncology. 42(16_suppl). 1007–1007. 2 indexed citations

Tsurutani, Junji, Yukinori Ozaki, Hiroshi Ishiguro, et al.. (2023). Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B). BMJ Open. 13(4). e070304–e070304. 3 indexed citations

Masuda, Hiroko, Yuko Tanabe, Koji Matsumoto, et al.. (2023). Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). The Breast. 71. 22–28. 13 indexed citations

Ozaki, Yukinori, Junji Tsurutani, Toru Mukohara, et al.. (2022). Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European Journal of Cancer. 171. 193–202. 24 indexed citations

Ozaki, Yukinori, Junji Tsurutani, Toru Mukohara, et al.. (2022). Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief. 45. 108558–108558. 1 indexed citations

Taira, Naruto, Kosuke Kashiwabara, Junji Tsurutani, et al.. (2022). Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.. PubMed. 76(6). 661–671. 1 indexed citations

Haratani, Koji, et al.. (2021). Successful treatment of a case of hormone receptor–positive metastatic extramammary Paget disease with tamoxifen. Investigational New Drugs. 40(1). 194–197. 1 indexed citations

10.

Yamashita, Toshinari, Norikazu Masuda, Shigehira Saji, et al.. (2020). Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 21(1). 391–391. 10 indexed citations

11.

Tsurutani, Junji, Fumikata Hara, Masahiro Kitada, et al.. (2020). Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. The Breast. 55. 63–68. 10 indexed citations

12.

Iwasa, Tsutomu, Junji Tsurutani, Satomi Watanabe, et al.. (2019). Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer. BMC Cancer. 19(1). 962–962. 2 indexed citations

13.

Sakai, Hitomi, Junji Tsurutani, Tsutomu Iwasa, et al.. (2018). HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer. 25(5). 605–613. 46 indexed citations

14.

Watanabe, Satomi, Masayuki Takeda, Takayuki Takahama, et al.. (2016). Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease. Investigational New Drugs. 34(3). 394–396. 11 indexed citations

15.

Tsurutani, Junji, Katsumasa Kuroi, Tsutomu Iwasa, et al.. (2015). Phase I study of weekly nab‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer. Cancer Science. 106(6). 734–739. 9 indexed citations

16.

Matsuoka, Hiromichi, Junji Tsurutani, Junko Tanizaki, et al.. (2013). Regression of brain metastases from breast cancer with eribulin: a case report. BMC Research Notes. 6(1). 541–541. 18 indexed citations

17.

Iwasa, Tsutomu, Junji Tsurutani, Hiromichi Matsuoka, et al.. (2013). Correlation of Malignancy and Sensitivity to Prior Treatment in Metastatic Breast Cancer Treated with Eribulin. Annals of Oncology. 24. ix32–ix32. 1 indexed citations

18.

Iwasa, Tsutomu, Isamu Okamoto, Minoru Suzuki, et al.. (2009). Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells. Clinical Cancer Research. 15(16). 5117–5125. 51 indexed citations

19.

Itaba, Soichi, Tsutomu Iwasa, Tadashi Misawa, et al.. (2007). Pneumocystis Pneumonia During Combined Therapy of Infliximab, Corticosteroid, and Azathioprine in a Patient with Crohn’s Disease. Digestive Diseases and Sciences. 52(6). 1438–1441. 16 indexed citations

20.

Iwasa, Tsutomu, et al.. (2006). An unusual duodenal polyp: pedunculated Brunner's glands hyperplasia. Gastrointestinal Endoscopy. 63(7). 1070–1071. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact